National International Holding Co. Receives CMA Approval for Treasury Share Transactions
National International Holding Company (NIH) has received approval from the Capital Markets Authority (CMA) to buy or sell up to 10% of its treasury shares.
Summary
NIH has been granted CMA approval to buy or sell up to 10% of its treasury shares over the next six months. This move is in line with the company's strategic investment policies and is subject to available financial resources.
In a significant development, National International Holding Company (NIH), a Kuwaiti Shareholding Company registered in the United Arab Emirates, has received approval from the Capital Markets Authority (CMA) to engage in the purchase or sale of up to 10% of its treasury shares. This approval is valid for a period of six months starting from August 27, 2024, and is contingent upon the availability of financial resources.
The decision aligns with NIH's strategic investment policies, which encompass diverse sectors including industrial, real estate, educational, technological, and investments across various markets such as Kuwait, Gulf countries, Europe, Australia, and America. The company's diversified investment approach aims to mitigate risks while maximizing returns.
CEO Mamdouh A. EL Sherbiny stated that this move is part of NIH's ongoing efforts to optimize its capital structure and enhance shareholder value. The approval permits NIH to buy or sell its shares, providing the company with greater flexibility in managing its equity base. It is worth noting that the impact on the company's financial position is expected to be neutral, as stated in the press release.
For investors, this development could be seen as a positive signal. The ability to buy back shares often indicates that the company believes its stock is undervalued, which could potentially lead to an increase in share price. Conversely, the option to sell shares provides NIH with an additional liquidity cushion, which could be beneficial in times of financial uncertainty.
However, it is crucial for investors to consider the broader market conditions and the company's overall financial health before making any investment decisions. NIH has a solid track record and a diversified portfolio, but market volatility and economic factors can always influence stock performance.
Given the current information and the company's strategic initiatives, it is advisable for investors to hold their positions. This recommendation is based on the potential for future growth balanced against the need for caution in a fluctuating market environment.
Source
Summary
National International Holding Company (NIH) has received approval from the Capital Markets Authority (CMA) to buy or sell up to 10% of its treasury shares. This approval is valid for six months starting from August 27, 2024, and is subject to the availability of financial resources, in accordance with Law no. 7 of 2010 and its subsequent amendments. The company states that this action will have no impact on its financial position. The letter was signed by Mamdouh A. EL Sherbiny, CEO and Board Member of NIH.
